Grifols SA Total Liab Over Time
| GRFS Stock | USD 6.99 1.08 13.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Grifols SA Performance and Grifols SA Correlation. Grifols |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grifols SA. If investors know Grifols will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grifols SA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Earnings Share 0.26 | Revenue Per Share 5.1545 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0287 |
The market value of Grifols SA ADR is measured differently than its book value, which is the value of Grifols that is recorded on the company's balance sheet. Investors also form their own opinion of Grifols SA's value that differs from its market value or its book value, called intrinsic value, which is Grifols SA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grifols SA's market value can be influenced by many factors that don't directly affect Grifols SA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grifols SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Grifols SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grifols SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare Grifols SA ADR and related stocks such as Novartis AG ADR, AstraZeneca PLC ADR, and GlaxoSmithKline PLC ADR Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVS | 17.6 B | 51.6 B | 55 B | 51.8 B | 54.5 B | 54.4 B | 55.2 B | 58.9 B | 66.9 B | 62.8 B | 75.4 B | 64 B | 58 B | 53.2 B | 45.6 B |
| AZN | 5.4 B | 29.4 B | 29.6 B | 32.6 B | 38.9 B | 41.6 B | 45.9 B | 46.7 B | 46.6 B | 46.8 B | 51.1 B | 66.1 B | 59.4 B | 62 B | 65.1 B |
| GSK | 703 M | 32.3 B | 34.7 B | 34.3 B | 35.7 B | 44.6 B | 54.1 B | 52.9 B | 54.4 B | 61.3 B | 59.6 B | 57.8 B | 50 B | 46.2 B | 25.5 B |
| BMY | 2.8 B | 17.1 B | 22.3 B | 23.4 B | 18.8 B | 17.3 B | 17.4 B | 21.7 B | 7.3 B | 78.2 B | 80.6 B | 73.3 B | 65.7 B | 65.7 B | 69 B |
| MRK | 2.3 B | 48.2 B | 50.7 B | 53.3 B | 49.5 B | 57 B | 55.1 B | 53.3 B | 55.8 B | 58.4 B | 66.2 B | 67.4 B | 63.1 B | 69 B | 72.5 B |
| GILD | 2.3 M | 10.4 B | 11.7 B | 10.8 B | 18.8 B | 32.7 B | 37.6 B | 49.8 B | 42.1 B | 39 B | 50.2 B | 46.9 B | 42 B | 39.4 B | 41.3 B |
| AMGN | 13.1 M | 29.8 B | 35.2 B | 44 B | 43.2 B | 43.5 B | 47.8 B | 54.7 B | 53.9 B | 50 B | 53.5 B | 54.5 B | 61.5 B | 90.9 B | 95.5 B |
| BIIB | 10.9 M | 2.6 B | 3.2 B | 3.2 B | 3.5 B | 10.1 B | 10.7 B | 11.1 B | 12.3 B | 13.9 B | 13.9 B | 12.9 B | 11.2 B | 12 B | 12.6 B |
| SNY | 3.2 B | 44.3 B | 42.9 B | 39 B | 41.1 B | 44.1 B | 47 B | 41.6 B | 52.4 B | 53.4 B | 51.2 B | 51.2 B | 51.6 B | 52.1 B | 38 B |
Grifols SA ADR and related stocks such as Novartis AG ADR, AstraZeneca PLC ADR, and GlaxoSmithKline PLC ADR Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| Grifols SA ADR | GRFS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 6.99
Additional Tools for Grifols Stock Analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.